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Introduction
We are interested in the mechanism of hstopoIIα because it is the target of several drugs currently being used in cancer therapy such as etoposide and doxorubicin (Harris and Hochhauser 1992; Isaacs, Davies et al. 1995; Burden and Osheroff 1998) . A number of these drugs work by trapping a DNA cleavage intermediate in which topo II is covalently attached to DNA. As a result, these drugs render the enzyme nucleolytic, inducing cytotoxicity. However, cancer cells become resistant over time (Harris and Hochhauser 1992) . A unique class of at-MDR mutants has been discovered, some of which are characterized by a single amino acid change in topo II. These amino acid substitutions have been mapped to the Gyr B' and Gyr A' domains (Mao, Yu et al. 1999; Wang, Mao et al. 2001 ) While some of these mutants have undergone initial characterization, very few biochemical experiments have been carried out on at-MDR mutants of hstopo IIα. We will attempt to further clarify the biochemical basis of at-MDR among hstopo IIα mutants to shed more light on the topo II enzymatic mechanism. To accomplish this goal, we have employed protein footprinting at cysteine residues using an alkylation/endoproteinase procedure coupled with liquid chromatographyelectrospray ionization-mass spectrometry (LC-ESI-MS). Structural changes of hstopo IIα lead to an alteration in the solvent-accessibility of the protein surface as domains open and close, resulting in varied sensitivity of amino acid residues towards footprinting reagents. This has allowed us to probe conformational changes of wild-type hstopo IIα in the presence and absence of anticancer drugs, DNA, and cofactors in order to further understand the hstopo IIα mechanism. Additionally, we will extend our studies to at-MDR mutants of hstopo IIα in order to better understand the biochemical basis of resistance among at-MDR mutants.
Using LC-ESI-MS, we have further demonstrated how newly identified topo II poisons and chemopreventive agents act to target the enzyme. Studies have shown that topo II can be poisoned by various mechanisms. (Liu, Rowe et al. 1983; Zechiedrich, Christiansen et al. 1989; Frydman, Marton et al. 1997; Kwok and Hurley 1998) . A mechanism for topo II poisoning was recently discovered in which thiol alkylation of topo II stimulates topo II-dependent DNA cleavage (Frydman, Marton et al. 1997; Wang, Mao et al. 2001) . A cysteineless mutant yeast topo II was found to be completely resistant to thiol-alkylating drugs, which implicates cysteine modification in the mediation of topo IIdirected DNA cleavage (Wang, Mao et al. 2001) . We have attempted to map the specific cysteine residue(s) involved in this mechanism by using an endoproteinase/ mass spectrometry footprinting approach.
Body

Protein Conformational Changes
To address the questions at hand, we have made progress towards accomplishing our research goals. Previously, recombinant hstopo IIα was created by fusing an HMK site and H 6 tag to the N-terminus of hstopo IIα. HMK-H 6 -hstopo IIα was purified by affinity and ion exchange chromatography; the purified protein displayed activity comparable to the wild type protein. The aforementioned construct was generated for the footprinting procedure initially developed during the first year, in which HMK-H 6 -hstopo IIα was treated with NTCB and subjected to alkaline denaturing conditions resulting in a ladder of peptide fragments which were radiolabeled, separated by SDS-PAGE and visualized by phosphorimaging. However, due to the difficulty encountered with the NTCB cysteine footprinting procedure, attempts were made to find an alternative footprinting procedure that could answer the same questions we began with. However, the HMK-H 6 -hstopo IIα construct was retained for use in the current development of an alternative cysteine footprinting approach.
To this end, an endoproteinase footprinting procedure utilizing mass spectrometry was developed. Initial experiments were targeted at successfully identifying cysteinecontaining peptides from a tryptic digest mixture by comparing spectra of reduced samples to those alkylated with iodoacetamide (IAM). For identification of alkylated cysteine-containing peptides, HMK-H 6 -hstopo IIα was treated with IAM and denatured. Upon removal of excess denaturant and IAM, the sample was completely digested with trypsin and subjected to LC-ESI-MS. This sample was then compared to that of a tryptic digest of HMK-H 6 -hstopo IIα which was not alkylated with IAM. The results from these experiments resulted in the successful identification of cysteine-containing peptide fragments covalently modified by IAM (Table 1) . Once it was established that we could identify all of the tryptic peptides containing cysteine residues, we began assessing the differential reactivities of the cysteines of HMK-H 6 -hstopo IIα. However, quantification of the alkylated cysteine-containing peptides is necessary for the validity of our approach. Thus, we developed a quantitiative mass spectrometric footprinting procedure utilizing both IAM as well as . To supplement and substantiate the biochemical data described thus far, an hstopo IIα structural model was constructed using S. cerevisiae topoisomerase II as a template. (Figure 2 ). Solvent contact surface analysis of the hstopo IIα homology model revealed four cysteines, Cys1008, Cys104, Cys216, and Cys405, as being the most solvent-accessible. These data agreed with that from the footprinting experiments, with the exception of Cys1008, which was shown to be one of the least reactive residues by our experimental data. One possible reason for this disagreement is that a sequence of 63 residues near Cys1008 was not modeled due to lack of S. cerevisiae template structure in this region. It is possible that the missing 63 amino acids actually shielded Cys1008 from the solvent and thus made it less accessible. However, the hstopo IIα homology model appears to be a useful tool for visualizing the position of each thiol relative to the global structure of hstopo IIα. Further experiments utilizing this protein in the S. cerevisiae template.
Cys427 was not modeled because corresponding structure was not present footprinting method to detect protein conformational changes were attempted. In these experiments, the protein was preincubated in the presence or absence of DNA, anticancer drugs and cofactors and was subsequently treated with D-IAM to take a "snapshot" of the protein conformational state. The protein was then treated with IAM and denatured to expose and alkylate the remaining cysteine residues as a reference point for those cysteines that are less solvent-accessible. The protein was digested with trypsin and subjected to LC-ESI-MS. However, upon plotting the relative ratios of cysteines that reacted with D-IAM to those that reacted with IAM, no significant differences in cysteine reactivity were observed in the presence or absence of DNA, anticancer drugs and cofactors.
Because no cysteine reactivity changes were observed using D-IAM followed by IAM, we attempted to carry out the footprinting procedure using a different reagent as the first alkylator. Kim et al. utilized a similar footprinting procedure to study tubulin-binding drugs and found that IAM was unable to satisfactorily locate sites of drug binding because the cysteines had little change in reactivity to IAM in the presence or absence of drug, similar to our results (Kim et al. 2004) . However, when they employed an alternative thiol alkylator, monobromobimane (mBrB), they were able to distinguish the site of drug binding as a result of lowered cysteine reactivity towards mBrB in the presence of a tubulin drug. The presumed cause of this result is due to the fact that mBrB is larger in size than IAM and is therefore more selective in its ability to react with cysteines that are more sterically hindered. Thus, we modified our footprinting procedure to include mBrB as the first cysteine alkylator. Initially, we used mBrB and IAM to test the relative thiol reactivity of hstopo IIα (see Table 1 for a list of mBrBmodified peaks). Because the mBrB/IAM combination yielded similar results in terms of relative cysteine reactivity, we used this technique to probe conformational changes of hstopo IIα. In our reactions, hstopo IIα was first preincubated in the presence or absence of anticancer drugs, DNA and cofactors and was subsequently treated with mBrB. Following this treatment, the enzyme was then alkylated with IAM under denaturing conditions and was digested with trypsin and subjected to LC-ESI-MS. The ratio of the intensity of the cysteine-containing trypsin fragments that reacted with mBrB versus the intensity of the fragments that reacted with IAM was determined and several notable changes in cysteine reactivity occurred. As seen in Figure 3 example of a residue whose relative reactivity to mBrB is not affected by the presence of anticancer drugs, DNA or ATP. Cys455, on the other hand, is a residue that has a marked decrease in reactivity to mBrB whenever the anticancer drug VM-26 (teniposide) is present. This could be the result of VM-26 locking hstopo IIα in a conformation that sterically hinders Cys455, or it could be the result of VM-26 directly blocking the site where Cys455 is located. It is interesting to note that Cys455 is near to the region in which hstopo IIα binds to and cleaves DNA, and VM-26 is a compound that affects hstopo IIα in such a way as to promote cleavage of DNA. Also of note is Cys862, which is also close to the region in which hstopo IIα binds DNA and is near the active site tyrosine residue involved in breaking the DNA backbone in a transesterification reaction. When VM-26 is present, we cannot detect reaction of Cys862 with mBrB, indicating that this region of hstopo IIα is either sterically hindered by the protein conformational change, or is blocked by binding of VM-26. In addition to VM-26, we also treated hstopo IIα with the compound ICRF-193, which is known to bind to the N-terminus of hstopo IIα and lock it in a closed conformation. It is interesting to note that several residues in the N-terminus are affected by the presence of ICRF-193. Particularly, Cys405, Cys300, and Cys170 are all residues on the exterior of the N-terminus of hstopo IIα that become more reactive to mBrB in the presence of ICRF-193 and ATP. When no ATP or ICRF-193 are present, the N-terminus adopts an open conformation, but when ICRF-193 and ATP are present, the N-terminus closes as seen in Figure2. Thus, it follows that these residues would react more readily with mBrB when ICRF-193 is present, because it will lock the N-termiumus closed and keep these residues more solvent-accessible. Cys455 is also more solvent accessible in the presence of ICRF-193, possibly as a result of the N-terminus being locked in the closed conformation, resulting in loss of steric hindrance of Cys455. Now that the protein footprinting method chosen is able to detect differences in cysteine reactivity in response to various reagents, we will extend our studies to further refine the method and then apply it to the study of at-MDR mutants of hstopo IIα in an attempt to better understand the biochemical basis of resistance of these mutants. For example, are the N-terminus or C-terminus of the at-MDR mutants adopting different conformational states than the wild type protein? How is the DNA binding domain affected in the at-MDR mutants? These are additional questions that we will address with the protein footprinting technique in hand.
Cysteine Binding sites
Using mass spectrometry, we have also identified sites of thiol alkylation of hstopo IIα by both anticancer drugs such as menadione and chemopreventive compounds such as diallyl trisulfide (DAT), which has been shown to induce topoisomerase II-mediated DNA cleavage. In this procedure, we directly observed thiol modification by identifying the appearance of new tryptic peptide fragments in alkylated samples. In this procedure, HMK-H 6 -hstopo IIα was incubated in the presence or absence of DNA and anticancer drugs or chemopreventive compounds. The reaction was quenched and HMK-H 6 -hstopo IIα was treated with excess IAM followed by trypsin digestion and LC-ESI-MS. In this procedure, it is feasible to discover sites of covalent modification by DAT, for example, by identifying fragments in DAT-treated samples that are not present in untreated samples. If the unique fragment corresponds to a molecular weight increase consistent with a reaction between DAT and a cysteine residue, then the site of modification can be identified. Moreover, the IAM-modified peptide will decrease in intensity or disappear altogether for samples that were pretreated with DAT, because their reaction with DAT precludes their reaction with IAM. Our preliminary data provides direct evidence that the chemopreventive compound DAT is reacting with thiol groups on HMK-H 6 -hstopo IIα. For example, as seen in Figure 3a , treatment with DAT results in the appearance of a new fragment consistent with a reaction between DAT and Cys104 contained in the peptide fragment MSCIR. Additionally, in the sample pretreated with DAT, the amount of IAM-modified peptide decreased ( Figure 3b ) because Cys104 had reacted with DAT, the first reagent it encountered, resulting in less reaction with the second reagent added, IAM, and hence a diminished signal for the IAM-modified peptide fragment. While data from LC-ESI-MS suggests that DAT modifies Cys104 to the greatest extent, additional thiols are modified as well. Thus, experiments are in progress to help determine the cysteine residues that are critical for this novel poisoning mechanism of hstopo IIα; site directed mutagenesis coupled with in vitro DNA cleavage assays will help to answer these remaining questions.
During the first year, we putatively identified menadione as having reacted with Cys427 by matrix-assisted laser desorption ionization (MALDI) MS. Preliminary results from LC-ESI-MS suggest that menadione reacts with additional thiol residues, albeit through indirect evidence. The indirect evidence is similar to that mentioned previously in which samples first treated with menadione followed by treatment with IAM exhibited diminished signals for cysteine-containing peptides modified with IAM, suggesting prior reaction with menadione precluding reaction with IAM. Additionally, chemopreventive compounds such as that found broccoli, benzyl isothiocyanate (BITC), have been tested, and indirect evidence also suggests reaction with thiol residues. Experiments are in progress to test a range of potential topoisomerase II poisons that act to inhibit the enzyme by thiol alkylation.
Key Research Accomplishments
• Overexpression of HMK-H 6 -hstopoIIα
• Purification of active HMK-H 6 -hstopoIIα
• Successful development and implementation of a footprinting technique using
LC-ESI-MS
• Reproducible identification of tryptic peptides containing cysteine residues
• Establishment of the relative thiol reactivity of hstopo IIα in native conditions
• Identification of conformational changes occurring in HMK-H 6 -hstopoIIα using cysteine footprinting
• Development of structural model of hstopo IIα based on homology to the S.
cerevisiae topoisomersase II structure
• Identification of thiol modification sites by anticancer drugs and chemopreventive compounds
• Putative verification of a new means by which thiol alkylators poison hstopo IIα
Conclusions
Human topoisomerase IIα is an essential enzyme that is the target of a number of anticancer drugs in clinical use, making the understanding of its catalytic mechanism very important. Thus, we are examining the mechanism of hstopo IIα using mass spectrometric cysteine footprinting in a procedure utilizing tryptic digestion coupled with LC-ESI-MS. Using LC-ESI-MS cysteine footprinting, we have assessed the differential thiol reactivities of the cysteine residues of hstopo IIα and have identified conformational changes occurring in the wild type enzyme. To complement the thiol reactivity results obtained by LC-ESI-MS, we have compared our data to a solvent contact surface analysis of an hstopo IIα structural model based on homology with its yeast counterpart. Moreover, we have found direct evidence of covalent thiol modification of hstopo IIα using LC-ESI-MS. These results exhibit the first direct evidence that thiol alkylation is indeed a novel mechanism of hstopo IIα poisoning. In the future, we will further clarify the biochemical basis of resistance among at-MDR mutants and we expect to complement our drug binding data with site-directed mutagenesis to pinpoint those cysteines most important in the thiol alkylation poisoning mechanism of hstopo IIα.
